# Veritas Intercontinental

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veritas-intercontinental

- Industry: Healthcare
- Headquarters: Madrid, Spain
- Website: www.veritasint.com
- Total disclosed funding: $21M
- Latest round: Series B (Oct 15, 2020)
- Investors on record: 3

## About

Founded in 201 and based in Madrid, Spain, Veritas Intercontinental is the international subsidiary of Veritas Genetics, which operates genetic testing platform intended to empower people about the quality and length of life. The company co-founded by Javier de Echevarría, Luis Izquierdo López, and Vincenzo Cirigliano and as of October 2020, the operates in Europe, Latin America, Middle East, and Japan. In October 2020, the company was received EUR 20 million from Charme Capital Partners and Amadeus Capital.

The company offers genetic testing solutions such as mygenome, myprenatal, mynewbornDNA, mycancerrriskDNA, mydiagnostic, and covid19, intended to support clinical researchers and physicians by offering a screening test for hereditary cancer risk.

The company generated by offering genetic tests and healthcare counseling.

Veritas Intercontinental plans to expand its international expansion and to develops new operational and technological capabilities.

## Funding rounds

- Series B, Oct 15, 2020, $5.9M — Amadeus Capital Partners, Charme Capital Partners, Stemar Capital Partners
- Series A, Jul 14, 2018, $15M — Amadeus Capital Partners, Charme Capital Partners

## Investors

- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Series A, Series B
- Charme Capital Partners (https://capitalatlas.ai/funds/charme-capital-partners) — Series A, Series B
- Stemar Capital Partners (https://capitalatlas.ai/funds/stemar-capital-partners) — Series B